Upstream Bio Documents

Upstream Bio SEC Filings

Upstream Bio Documents 2026

Upstream Bio Stock analysis

Upstream Bio Upstream Bio, Inc. develops verekitug, a monoclonal antibody targeting TSLP, a cytokine involved in inflammatory diseases. The company focuses on severe respiratory disorders, conducting Phase II trials for severe asthma and chronic rhinosinusitis with nasal polyps. Verekitug is positioned as the only known antagonist in development targeting TSLP, which is a clinically validated driver of inflammation upstream of multiple immune pathways. The firm plans to expand into chronic obstructive pulmonary disease (COPD) development after current trials. The company operates through clinical-stage biotechnology development, targeting inflammatory diseases with an initial focus on severe respiratory conditions. Verekitug is the sole product in development, with no other products or brands mentioned. The target market includes patients with severe asthma, chronic rhinosinusitis with nasal polyps, and potentially COPD patients in the future. The company's revenue model is based on future drug sales and potential partnerships, though specific financial details are not disclosed in the description. Upstream Bio, Inc. is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, with 52 full-time employees. It went public via IPO on October 11, 2024. The company's primary product, verekitug, is the only known antagonist in development targeting TSLP, a cytokine produced by epithelial cells in the lung, gastrointestinal tract, and skin. TSLP is classified as an alarmin, part of a class of epithelial cytokines including IL-25 and IL-33, which are clinically validated drivers of inflammatory responses.